New blood cancer injection given green light by UK regulators

5 August 2014
ukparliament-big

Patients in the UK with one of the most common forms of blood cancercan now benefit from a new injection. MabThera (rituximab) subcutaneous (SC) can be administered in around five minutes, compared to the current two and a half hour intravenous (IV) infusion.

This faster way of delivering MabThera, from Swiss pharma major Roche (ROG: SIX), will now be available to around 2,400 patients per year with follicular lymphoma (FL), a form of non-Hodgkin lymphoma (NHL). MabThera SC has been granted a license for use in the UK based on data from the SABRINA study,which showed that switching from IV to SC administration provides comparable efficacy of MabThera in patients with FL.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Pharmaceutical